France · Delayed Price · Currency is EUR bioMérieux Statistics
Total Valuation
bioMérieux has a market cap or net worth of EUR 12.83 billion. The enterprise value is 12.96 billion.
| Market Cap | 12.83B |
| Enterprise Value | 12.96B |
Important Dates
The last earnings date was Thursday, October 30, 2025.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
bioMérieux has 118.07 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 118.07M |
| Shares Outstanding | 118.07M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 18.21% |
| Float | 44.73M |
Valuation Ratios
The trailing PE ratio is 34.29 and the forward PE ratio is 22.31. bioMérieux's PEG ratio is 2.20.
| PE Ratio | 34.29 |
| Forward PE | 22.31 |
| PS Ratio | 3.11 |
| PB Ratio | 3.26 |
| P/TBV Ratio | 4.59 |
| P/FCF Ratio | 29.21 |
| P/OCF Ratio | 16.29 |
| PEG Ratio | 2.20 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.55, with an EV/FCF ratio of 29.50.
| EV / Earnings | 34.30 |
| EV / Sales | 3.15 |
| EV / EBITDA | 12.55 |
| EV / EBIT | 18.42 |
| EV / FCF | 29.50 |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.27 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.49 |
| Debt / FCF | 1.15 |
| Interest Coverage | 45.70 |
Financial Efficiency
Return on equity (ROE) is 9.49% and return on invested capital (ROIC) is 9.90%.
| Return on Equity (ROE) | 9.49% |
| Return on Assets (ROA) | 8.23% |
| Return on Invested Capital (ROIC) | 9.90% |
| Return on Capital Employed (ROCE) | 16.14% |
| Revenue Per Employee | 285,226 |
| Profits Per Employee | 26,150 |
| Employee Count | 14,754 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, bioMérieux has paid 138.40 million in taxes.
| Income Tax | 138.40M |
| Effective Tax Rate | 27.18% |
Stock Price Statistics
The stock price has increased by +10.13% in the last 52 weeks. The beta is 0.65, so bioMérieux's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +10.13% |
| 50-Day Moving Average | 111.15 |
| 200-Day Moving Average | 116.57 |
| Relative Strength Index (RSI) | 48.64 |
| Average Volume (20 Days) | 114,448 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioMérieux had revenue of EUR 4.12 billion and earned 377.90 million in profits. Earnings per share was 3.17.
| Revenue | 4.12B |
| Gross Profit | 2.32B |
| Operating Income | 703.80M |
| Pretax Income | 509.20M |
| Net Income | 377.90M |
| EBITDA | 999.50M |
| EBIT | 703.80M |
| Earnings Per Share (EPS) | 3.17 |
Balance Sheet
The company has 380.50 million in cash and 506.40 million in debt, giving a net cash position of -125.90 million or -1.07 per share.
| Cash & Cash Equivalents | 380.50M |
| Total Debt | 506.40M |
| Net Cash | -125.90M |
| Net Cash Per Share | -1.07 |
| Equity (Book Value) | 3.94B |
| Book Value Per Share | 33.32 |
| Working Capital | 1.27B |
Cash Flow
In the last 12 months, operating cash flow was 787.70 million and capital expenditures -348.30 million, giving a free cash flow of 439.40 million.
| Operating Cash Flow | 787.70M |
| Capital Expenditures | -348.30M |
| Free Cash Flow | 439.40M |
| FCF Per Share | 3.72 |
Margins
Gross margin is 56.27%, with operating and profit margins of 17.08% and 9.17%.
| Gross Margin | 56.27% |
| Operating Margin | 17.08% |
| Pretax Margin | 12.35% |
| Profit Margin | 9.17% |
| EBITDA Margin | 24.25% |
| EBIT Margin | 17.08% |
| FCF Margin | 10.66% |
Dividends & Yields
This stock pays an annual dividend of 0.90, which amounts to a dividend yield of 0.84%.
| Dividend Per Share | 0.90 |
| Dividend Yield | 0.84% |
| Dividend Growth (YoY) | 5.88% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | 0.75% |
| Earnings Yield | 2.94% |
| FCF Yield | 3.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 20, 2017. It was a forward split with a ratio of 3.
| Last Split Date | Sep 20, 2017 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
bioMérieux has an Altman Z-Score of 6.89 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.89 |
| Piotroski F-Score | 7 |